Jacobson et al described a new staging system for multiple myeloma based on the experience of the Southwest Oncology Group (SWOG). The authors are from multiple university hospitals across the United States.
Parameters:
(1) serum beta-2 microglobulin in mg/L
(2) serum albumin in g/L
|
Beta-2 Microglobulin |
Albumin |
Stage |
|
< 2.5 mg/L |
NA |
1 |
|
2.5 - 5.4 mg/L |
NA |
2 |
|
>= 5.5 mg/L |
>= 3.0 g/dL |
3 |
|
>= 5.5 mg/L |
< 3.0 g/dL |
4 |
|
Stage |
Median Overall Survival |
1 Year Mortality |
Long Term (>= 5 Years) Event Free Survival |
|
1 |
55 months |
8% |
24% |
|
2 |
40 months |
13% |
15% |
|
3 |
24 months |
27% |
11% |
|
4 |
16 months |
40% |
4% |
The authors also described a pruned regression tree based on beta-2 microglobulin, albumin, total calcium and number of bone lesions.
|
Beta-2 Microglobulin |
Calcium |
Number Bone Lesions |
Albumin |
Hazard Ratio |
|
< 2.5 mg/L |
NA |
NA |
NA |
1 |
|
2.5 - 5.4 |
< 10 mg/dL |
NA |
NA |
1.35 |
|
2.5 - 5.4 |
>= 10 mg/dL |
NA |
NA |
1.93 |
|
>= 5.5 |
NA |
< 3 |
NA |
1.95 |
|
>= 5.5 |
NA |
>=3 |
>= 35 g/L |
2.36 |
|
>= 5.5 |
NA |
>=3 |
< 35 g/L |
3.67 |
where:
• Figure 5 expresses calcium in mg/dL but the previous tables use mmol/L.
Specialty: Hematology Oncology
ICD-10: ,
